Studi relawan sehat di Cicero, IL
16 studi di lokasi sekitar Cicero menerima relawan sehat — orang tanpa kondisi yang sedang diteliti. Banyak studi membayar peserta atas waktu dan perjalanan mereka; jumlah pembayaran ditentukan oleh masing-masing studi, jadi tanyakan kepada tim studi.
Teks studi resmi (Bahasa Inggris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- OSF Little Company of Mary Medical Center, Evergreen Park · 9 mi jauhnya
- Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Menerima pesertaSukarelawan sehat diterima
- Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
- Advocate Outpatient Center - Oak Lawn, Oak Lawn · 9 mi jauhnya
- Advocate High Tech Medical Park, Palos Heights · 12 mi jauhnya
Family Communications After Genetic Testing
Menerima pesertaSukarelawan sehat diterima
- Advocate Christ Medical Center, Oak Lawn · 9 mi jauhnya
- Advocate Outpatient Center - Oak Lawn, Oak Lawn · 9 mi jauhnya
- Advocate High Tech Medical Park, Palos Heights · 12 mi jauhnya
Evaluation of Approved Contact Lenses (CR-6657)
Menerima pesertaSukarelawan sehat diterima
- Franklin Park Eye Center, P.C., Franklin Park · 8 mi jauhnya
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Menerima pesertaFase 1/2Sukarelawan sehat diterima
- DM Clinical Research - Chicago- Site Number : 8400050, Melrose Park · 7 mi jauhnya
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
Menerima pesertaFase 3Sukarelawan sehat diterima
- DM Clinical Research, Melrose Park · 7 mi jauhnya
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)
Menerima pesertaFase 3Sukarelawan sehat diterima
- Edward Hines Jr. VA Hospital, Hines, IL, Hines · 4 mi jauhnya
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
Menerima pesertaFase 1/2Sukarelawan sehat diterima
- AMR Chicago- Site Number : 8400005, Oak Brook · 9 mi jauhnya
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
Menerima pesertaFase 3Sukarelawan sehat diterima
- DM Clinical Research - Chicago, Melrose Park · 7 mi jauhnya
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Menerima pesertaFase 4Sukarelawan sehat diterima
- Hines VA Medical Center, Hines · 4 mi jauhnya
Shield Post-Approval Study Protocol
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Southwest Gastroenterology (SWG), Oak Lawn · 9 mi jauhnya
- Southwest Gastroenterology (SWG), Oak Lawn · 9 mi jauhnya
Improving Safety, Patient Experience and Equity Through Shared Decision-making Huddles in Labor
Menerima pesertaSukarelawan sehat diterima
- Loyola MacNeal Hospital, Berwyn · 2 mi jauhnya
- Loyola University Medical Center, Maywood · 5 mi jauhnya
- UChicago Medicine AdventHealth Hinsdale, Hinsdale · 10 mi jauhnya
- dan 1 lainnya
Medrol Dosepak for Outpatient Total Knee Arthroplasty
Menerima pesertaFase 4Sukarelawan sehat diterima
- Rush Oak Brook Outpatient Center, Oak Brook · 9 mi jauhnya
Caris Biorepository Research Protocol
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Hope and Healing Cancer Services, Hinsdale · 10 mi jauhnya
Spinal Cord Stimulation for Functional Recovery in Humans With Tetraplegia
Menerima pesertaSukarelawan sehat diterima
- Edward Hines Jr. VA Hospital, Hines, IL, Hines · 4 mi jauhnya
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
Menerima pesertaFase 2Sukarelawan sehat diterima
- Edward Hines Jr. VA Hospital, Hines, IL, Hines · 4 mi jauhnya
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.